These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29798795)

  • 1. Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy: The VANISH Trial.
    Coyle K; Coyle D; Nault I; Parkash R; Healey JS; Gray CJ; Gardner MJ; Sterns LD; Essebag V; Hruczkowski T; Blier L; Wells GA; Tang ASL; Stevenson WG; Sapp JL
    JACC Clin Electrophysiol; 2018 May; 4(5):660-668. PubMed ID: 29798795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
    Parkash R; Nault I; Rivard L; Gula L; Essebag V; Nery P; Tung S; Raymond JM; Sterns L; Doucette S; Wells G; Tang ASL; Stevenson WG; Sapp JL
    Circ Arrhythm Electrophysiol; 2018 Jan; 11(1):e005663. PubMed ID: 29305400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
    Sapp JL; Wells GA; Parkash R; Stevenson WG; Blier L; Sarrazin JF; Thibault B; Rivard L; Gula L; Leong-Sit P; Essebag V; Nery PB; Tung SK; Raymond JM; Sterns LD; Veenhuyzen GD; Healey JS; Redfearn D; Roux JF; Tang AS
    N Engl J Med; 2016 Jul; 375(2):111-21. PubMed ID: 27149033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular Tachycardia and ICD Therapy Burden With Catheter Ablation Versus Escalated Antiarrhythmic Drug Therapy.
    Samuel M; Healey JS; Nault I; Sterns LD; Essebag V; Gray C; Hruczkowski T; Gardner M; Parkash R; Sapp JL
    JACC Clin Electrophysiol; 2023 Jun; 9(6):808-821. PubMed ID: 37380314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial.
    Deyell MW; Doucette S; Parkash R; Nault I; Gula L; Gray C; Gardner M; Sterns LD; Healey JS; Essebag V; Sapp JL
    Europace; 2022 Jul; 24(7):1112-1118. PubMed ID: 35030257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial.
    Samuel M; Rivard L; Nault I; Gula L; Essebag V; Parkash R; Sterns LD; Khairy P; Sapp JL
    Europace; 2022 Jul; 24(6):948-958. PubMed ID: 34964475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base.
    Chen Y; Gomes M; Garcia JV; Hunter RJ; Chow AW; Dhinoja M; Schilling RJ; Lowe M; Lambiase PD
    Open Heart; 2020; 7(1):e001155. PubMed ID: 32076562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
    Arenal Á; Ávila P; Jiménez-Candil J; Tercedor L; Calvo D; Arribas F; Fernández-Portales J; Merino JL; Hernández-Madrid A; Fernández-Avilés FJ; Berruezo A
    J Am Coll Cardiol; 2022 Apr; 79(15):1441-1453. PubMed ID: 35422240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia.
    Calkins H; Bigger JT; Ackerman SJ; Duff SB; Wilber D; Kerr RA; Bar-Din M; Beusterien KM; Strauss MJ
    Circulation; 2000 Jan; 101(3):280-8. PubMed ID: 10645924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial.
    Chew DS; Li Y; Cowper PA; Anstrom KJ; Piccini JP; Poole JE; Daniels MR; Monahan KH; Davidson-Ray L; Bahnson TD; Al-Khalidi HR; Lee KL; Packer DL; Mark DB;
    Circulation; 2022 Aug; 146(7):535-547. PubMed ID: 35726631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Noninducibility on Outcomes of Ventricular Tachycardia Ablation: A VANISH Substudy.
    Essebag V; Joza J; Nery PB; Doucette S; Nault I; Rivard L; Gula L; Deyell M; Raymond JM; Lane C; Sapp JL
    JACC Clin Electrophysiol; 2018 Jul; 4(7):911-919. PubMed ID: 30025692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction.
    Chew DS; Loring Z; Anand J; Fudim M; Lowenstern A; Rymer JA; Weimer KED; Atwater BD; DeVore AD; Exner DV; Noseworthy PA; Yancy CW; Mark DB; Piccini JP
    Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007094. PubMed ID: 33280436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy.
    Larsen G; Hallstrom A; McAnulty J; Pinski S; Olarte A; Sullivan S; Brodsky M; Powell J; Marchant C; Jennings C; Akiyama T;
    Circulation; 2002 Apr; 105(17):2049-57. PubMed ID: 11980684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia.
    Cheng CH; Sanders GD; Hlatky MA; Heidenreich P; McDonald KM; Lee BK; Larson MS; Owens DK
    Ann Intern Med; 2000 Dec; 133(11):864-76. PubMed ID: 11103056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease.
    Inada K; Roberts-Thomson KC; Seiler J; Steven D; Tedrow UB; Koplan BA; Stevenson WG
    Heart Rhythm; 2010 Jun; 7(6):740-4. PubMed ID: 20167290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial.
    Al-Khatib SM; Daubert JP; Anstrom KJ; Daoud EG; Gonzalez M; Saba S; Jackson KP; Reece T; Gu J; Pokorney SD; Granger CB; Hess PL; Mark DB; Stevenson WG
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):151-7. PubMed ID: 25332150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH.
    Gula LJ; Doucette S; Leong-Sit P; Tang ASL; Parkash R; Sarrazin JF; Thibault B; Essebag V; Tung SK; Deyell MW; Raymond JM; Lane C; Nery PB; Veenhuyzen GD; Redfearn DP; Healey JS; Roux JF; Giddens K; Sapp JL
    J Cardiovasc Electrophysiol; 2018 Mar; 29(3):421-434. PubMed ID: 29316012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings.
    Della Bella P; De Ponti R; Uriarte JA; Tondo C; Klersy C; Carbucicchio C; Storti C; Riva S; Longobardi M
    Eur Heart J; 2002 Mar; 23(5):414-24. PubMed ID: 11846499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.